M C Riddle

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies
    M C Riddle
    Department of Medicine, Oregon Health and Science University, Portland, OR, USA
    Diabetes Obes Metab 15:819-25. 2013
  2. pmc Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 36:2489-96. 2013
  3. pmc Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 36:2497-503. 2013
  4. doi request reprint Reevaluating goals of insulin therapy: perspectives from large clinical trials
    Matthew C Riddle
    Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mailcode L345, Portland, OR 97239, USA
    Endocrinol Metab Clin North Am 41:41-56. 2012
  5. ncbi request reprint The underuse of insulin therapy in North America
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, OR 97201, USA
    Diabetes Metab Res Rev 18:S42-9. 2002
  6. pmc Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 33:983-90. 2010
  7. ncbi request reprint Making the transition from oral to insulin therapy
    Matthew C Riddle
    Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97201, USA
    Am J Med 118:14S-20S. 2005
  8. ncbi request reprint Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, 3181 SW Sam Jackson Park Drive, Portland, OR 97239 3098, USA
    Endocrinol Metab Clin North Am 34:77-98. 2005
  9. ncbi request reprint Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University L 345, Portland, Oregon 97239 3098, USA
    J Clin Endocrinol Metab 93:372-4. 2008
  10. ncbi request reprint Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor
    Matthew C Riddle
    Section of Diabetes L 345, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
    Diabetes Care 31:S125-30. 2008

Detail Information

Publications33

  1. doi request reprint Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies
    M C Riddle
    Department of Medicine, Oregon Health and Science University, Portland, OR, USA
    Diabetes Obes Metab 15:819-25. 2013
    ..0% or the risk of experiencing hypoglycaemia after the addition of insulin glargine to oral therapy in type 2 diabetes...
  2. pmc Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 36:2489-96. 2013
    ....
  3. pmc Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 36:2497-503. 2013
    ..We examined the efficacy and safety of lixisenatide in patients with HbA1c still elevated after initiation of insulin glargine...
  4. doi request reprint Reevaluating goals of insulin therapy: perspectives from large clinical trials
    Matthew C Riddle
    Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mailcode L345, Portland, OR 97239, USA
    Endocrinol Metab Clin North Am 41:41-56. 2012
    ..This article surveys recent epidemiologic studies and interventional trials, examines the current understanding of the natural history of type 2 diabetes, and proposes new goals and tactics for optimizing insulin therapy...
  5. ncbi request reprint The underuse of insulin therapy in North America
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, OR 97201, USA
    Diabetes Metab Res Rev 18:S42-9. 2002
    ..Several new treatment options are discussed...
  6. pmc Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 33:983-90. 2010
    ..As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality...
  7. ncbi request reprint Making the transition from oral to insulin therapy
    Matthew C Riddle
    Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97201, USA
    Am J Med 118:14S-20S. 2005
    ..Future studies should consider not only the ability of regimens to reach hemoglobin A(1c) targets but also the burden of adverse effects accompanying this effort with a given method...
  8. ncbi request reprint Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, 3181 SW Sam Jackson Park Drive, Portland, OR 97239 3098, USA
    Endocrinol Metab Clin North Am 34:77-98. 2005
    ..For now, systematic application of the scheme (see Fig. 4) should improve the success of treatment greatly from its currently disappointing level...
  9. ncbi request reprint Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary
    Matthew C Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University L 345, Portland, Oregon 97239 3098, USA
    J Clin Endocrinol Metab 93:372-4. 2008
  10. ncbi request reprint Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor
    Matthew C Riddle
    Section of Diabetes L 345, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
    Diabetes Care 31:S125-30. 2008
  11. ncbi request reprint Combining sulfonylureas and other oral agents
    M Riddle
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Am J Med 108:15S-22S. 2000
    ..Later in the course of the disease, the use of combinations of oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients...
  12. ncbi request reprint The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes Care 26:3080-6. 2003
    ..To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c)...
  13. ncbi request reprint Pramlintide: an agent for glycemic control plus weight control?
    Matthew C Riddle
    Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Diabetes Technol Ther 4:63-5. 2002
  14. doi request reprint Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus
    D M Karl
    The Endocrine Clinic, Portland, OR 97216, USA
    Diabetes Obes Metab 15:622-8. 2013
    ..The aim of this study was to obtain information about clinical characteristics which might predict risk of hypoglycaemia during initiation of basal insulin...
  15. ncbi request reprint Timely initiation of basal insulin
    Matthew C Riddle
    Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Am J Med 116:3S-9S. 2004
    ..To maintain the recommended <7% HbA(1c) target level of control, treatments that target postprandial hyperglycemia will have to be added to basal insulin later on, as endogenous insulin continues to decline...
  16. doi request reprint Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  17. ncbi request reprint The Treat-to-Target Trial and related studies
    Matthew C Riddle
    Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Sciences University, Portland, USA
    Endocr Pract 12:71-9. 2006
    ..To describe the rationale for, and the findings of, the Treat-to-Target Trial and to compare its results with those of two subsequent studies based on the same concepts...
  18. ncbi request reprint Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine
    M C Riddle
    Department of Medicine, Oregon Health Sciences University, Portland, USA
    Horm Metab Res 28:430-3. 1996
    ..The available evidence suggests this form of combined therapy is suitable for routine use...
  19. ncbi request reprint Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
    Matthew C Riddle
    Oregon Health and Sciences University, Portland, OR, USA
    Diabetes Metab Res Rev 22:483-91. 2006
    ..This analysis examines the effects of 82 weeks of exenatide treatment for participants in these earlier 30-week trials...
  20. ncbi request reprint Current oral agents for type 2 diabetes. Many options, but which to choose when?
    Andrew J Ahmann
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Rd, OP05, Portland, OR 97201 3098, USA
    Postgrad Med 111:32-4, 37-40, 43-6. 2002
    ..In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect...
  21. doi request reprint Influence of glucocorticoids and growth hormone on insulin sensitivity in humans
    K C J Yuen
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, OR, USA
    Diabet Med 30:651-63. 2013
    ....
  22. ncbi request reprint Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1
    Matthew C Riddle
    Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
    Diabetes Care 29:435-49. 2006
  23. ncbi request reprint Timely addition of insulin to oral therapy for type 2 diabetes
    Matthew C Riddle
    Diabetes Care 25:395-6. 2002
  24. ncbi request reprint Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
    Matthew C Riddle
    J Clin Endocrinol Metab 88:528-30. 2003
  25. ncbi request reprint What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?
    Andrew J Ahmann
    Am J Med 116:276-8. 2004
  26. ncbi request reprint Type 2 diabetes: the role of basal insulin therapy
    Derek LeRoith
    J Fam Pract 53:215-22. 2004
  27. ncbi request reprint Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
    Hans U Janka
    Zentralkrankenhaus, Bremen Nord, II Medizinische Abteilung, Hammersbecker Str 228, 28755 Bremen, Germany
    Diabetes Care 28:254-9. 2005
    ..To compare the efficacy and safety of adding once-daily basal insulin versus switching to twice-daily premixed insulin in type 2 diabetic patients insufficiently controlled by oral antidiabetic agents (OADs)...
  28. ncbi request reprint Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    David M Kendall
    International Diabetes Center and University of Minnesota, Minmneapolis, MN, USA
    Diabetes Care 28:1083-91. 2005
    ..This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy...
  29. ncbi request reprint Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
    Hertzel Gerstein
    Am Heart J 155:26-32, 32.e1-6. 2008
    ..Thus, targeting normal fasting glucose levels with insulin may reduce CV events. Previous studies suggest that omega-3 fatty acid supplements may reduce CV death; however, their effect in high-risk dysglycemic individuals is not known...
  30. ncbi request reprint Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus
    Peter Mullins
    Department of Statistics, University of Auckland, Auckland, New Zealand
    Clin Ther 29:1607-19. 2007
    ..The model was then used to compare rates of hypoglycemia associated with use of these insulins...
  31. ncbi request reprint Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Hertzel C Gerstein
    Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Am J Cardiol 99:34i-43i. 2007
    ..It will also provide information on how to safely approach near-normal levels of glucose control in clinical practice and evidence to support future clinical guidelines for diabetes management in older adults...
  32. ncbi request reprint ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations
    Harold E Lebovitz
    Endocr Pract 12:6-12. 2006